.September 2, 2024 Monday 04:00:04 PM

In the dermatology therapeutics sector, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) faces challenges with a ROIC of -257.28% and a WACC of 10.37%, indicating struggles in generating returns exceeding its cost of capital. Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) leads peers with the best ROIC/WACC ratio of -4.20, showcasing better financial performance. Overall, the industry grapples with generating investment returns surpassing capital costs, emphasizing the need to assess financial metrics alongside market position and product pipeline for informed decision-making.